C12N 2710/16071
Demonstrated in vivo effect
C12N2710/16071 (Demonstrated in vivo effect) appears on 18 US grants and 30 published applications in this corpus.
Search patents in C12N- Granted patents
- 18
- Published applications
- 30
- Assignees
- 16
- Inventors
- 45
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 3 | 4 |
| 2015 | 0 | 0 |
| 2016 | 3 | 1 |
| 2017 | 0 | 3 |
| 2018 | 1 | 1 |
| 2019 | 1 | 4 |
| 2020 | 4 | 1 |
| 2021 | 0 | 5 |
| 2022 | 0 | 0 |
| 2023 | 2 | 1 |
| 2024 | 1 | 3 |
| 2025 | 1 | 1 |
| 2026 | 2 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for the treatment of skin diseases16 Jun 2026US 12,655,447 B2Krystal Biotech, Inc.
- Compositions and methods for delivering CFTR polypeptides13 Jan 2026US 12,522,636 B2Krystal Biotech, Inc.
- Chimeric antigen receptor constructs and their use in CAR-T cells25 Nov 2025US 12,479,890 B2The University of North Carolina at Chapel Hill
- Virus25 Jun 2024US 12,016,949 B2iosBio Ltd
- Epstein-Barr virus-like particles with broadened antigenic spectrum7 Nov 2023US 11,806,395 B2Deutsches Krebsforschungszentrum
- Compositions and Methods for Delivering CFTR Polypeptides30 Apr 2026US 2026/0116934 A1Krystal Biotech, Inc.
- Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors2 Apr 2026US 2026/0091069 A1Virogin Biotech Canada Ltd
- Replication-competent controlled alpha-herpesvirus vectors and uses therefore3 Jul 2025US 2025/0213676 A1HSF Pharmaceuticals SA
- Virus14 Nov 2024US 2024/0374509 A1iosBio Ltd
- Vaccine compositions of herpesvirus envelope protein combinations to induce immune response15 Aug 2024US 2024/0270796 A1The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Most cited
By later US patents